Enhanced expression of WD repeat-containing protein 35 via nuclear factor-kappa B activation in bupivacaine-treated Neuro2a cells.
Enhanced expression of WD repeat-containing protein 35 via nuclear factor-kappa B activation in bupivacaine-treated Neuro2a cells.
复制标题
DOI:
10.1371/journal.pone.0086336
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Okada S
中科院分区:
文献类型:
--
作者:
Huang L;Kondo F;Harato M;Feng GG;Ishikawa N;Fujiwara Y;Okada S
The family of WD repeat proteins comprises a large number of proteins and is involved in a wide variety of cellular processes such as signal transduction, cell growth, proliferation, and apoptosis. Bupivacaine is a sodium channel blocker administered for local infiltration, nerve block, epidural, and intrathecal anesthesia. Recently, we reported that bupivacaine induces reactive oxygen species (ROS) generation and p38 mitogen-activated protein kinase (MAPK) activation, resulting in an increase in the expression of WD repeat-containing protein 35 (WDR35) in mouse neuroblastoma Neuro2a cells. It has been shown that ROS activate MAPK through phosphorylation, followed by activation of nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1). The present study was undertaken to test whether NF-κB and c-Jun/AP-1 are involved in bupivacaine-induced WDR35 expression in Neuro2a cells. Bupivacaine activated both NF-κB and c-Jun in Neuro2a cells. APDC, an NF-κB inhibitor, attenuated the increase in NF-κB activity and WDR35 protein expression in bupivacaine-treated Neuro2a cells. GW9662, a selective peroxisome proliferator-activated receptor-γ antagonist, enhanced the increase in NF-κB activity and WDR35 protein expression in bupivacaine-treated Neuro2a cells. In contrast, c-Jun siRNA did not inhibit the bupivacaine-induced increase in WDR35 mRNA expression. These results indicate that bupivacaine induces the activation of transcription factors NF-κB and c-Jun/AP-1 in Neuro2a cells, while activation of NF-κB is involved in bupivacaine-induced increases in WDR35 expression.
登录
查看更多内容
影响因子:
2.4
作者:
Harato M;Huang L;Kondo F;Tsunekawa K;Feng GG;Fan JH;Ishikawa N;Fujiwara Y;Okada S
通讯作者:
Okada S
影响因子:
5.8
作者:
Rahman, I;Marwick, J;Kirkham, P
通讯作者:
Kirkham, P
DOI:
10.1155/2013/470975
发表时间:
2013
期刊:
Evidence-based complementary and alternative medicine : eCAM
影响因子:
--
作者:
Liu ZJ;Liu W;Liu L;Xiao C;Wang Y;Jiao JS
通讯作者:
Jiao JS
影响因子:
3.7
作者:
Berisha SZ;Serre D;Schauer P;Kashyap SR;Smith JD
通讯作者:
Smith JD
影响因子:
5.1
作者:
Chen, Yu-Chang;Wu, Jui-Sheng;Lin, Teng-Nan
通讯作者:
Lin, Teng-Nan